# Biotricity Inc.: overview BTCY · OTC · CIK 1630113 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/btcy.md) · [Financials](/companies/btcy/financials.md) · [Filings](/companies/btcy/filings.md) · [Insiders](/companies/btcy/insiders.md) Latest reported revenue: [$4.3m](/filings/0001493152-26-039209.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 19, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-039209). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [3,267](/filings/0001493152-25-023361.md) | [3,619](/filings/0001493152-26-006211.md) | [3,703 d](/filings/0001493152-26-033207.md) | [3,874](/filings/0001493152-26-039209.md) | [3,886](/filings/0001493152-25-023361.md) | [3,988](/filings/0001493152-26-006211.md) | [4,251 d](/filings/0001493152-26-033207.md) | [4,277](/filings/0001493152-26-039209.md) | | Gross margin | % | [75.3%](/filings/0001493152-25-023361.md) | [76.4%](/filings/0001493152-26-006211.md) | [80.4% d](/filings/0001493152-26-033207.md) | [80.5%](/filings/0001493152-26-039209.md) | [81.9%](/filings/0001493152-25-023361.md) | [81.5%](/filings/0001493152-26-006211.md) | [80.0% d](/filings/0001493152-26-033207.md) | [82.6%](/filings/0001493152-26-039209.md) | | Operating margin | % | [(9.4%)](/filings/0001493152-25-023361.md) | [(4.7%)](/filings/0001493152-26-006211.md) | [(23.1%) d](/filings/0001493152-26-033207.md) | [7.3%](/filings/0001493152-26-039209.md) | [7.0%](/filings/0001493152-25-023361.md) | [11.1%](/filings/0001493152-26-006211.md) | [16.3% d](/filings/0001493152-26-033207.md) | [3.7%](/filings/0001493152-26-039209.md) | | Net margin | % | [(47.8%)](/filings/0001493152-25-023361.md) | [(34.0%)](/filings/0001493152-26-006211.md) | [(52.3%) d](/filings/0001493152-26-033207.md) | [(17.3%)](/filings/0001493152-26-039209.md) | [(17.8%)](/filings/0001493152-25-023361.md) | [(18.0%)](/filings/0001493152-26-006211.md) | [(7.6%) d](/filings/0001493152-26-033207.md) | [(22.4%)](/filings/0001493152-26-039209.md) | | Diluted EPS | $ per share | [(0.07)](/filings/0001493152-25-023361.md) | [(0.05)](/filings/0001493152-26-006211.md) | not reported | [(0.03)](/filings/0001493152-26-039209.md) | [(0.03)](/filings/0001493152-25-023361.md) | [(0.04)](/filings/0001493152-26-006211.md) | not reported | [(0.05)](/filings/0001493152-26-039209.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.7](/filings/0001493152-23-022974.md) | [9.6](/filings/0001493152-24-025344.md) | [12.1](/filings/0001641172-25-020105.md) | [13.8](/filings/0001493152-26-033207.md) | [16.0](/filings/0001493152-26-033207.md) | | Gross margin | % | [59.7%](/filings/0001493152-23-022974.md) | [56.5%](/filings/0001493152-24-025344.md) | [69.3%](/filings/0001641172-25-020105.md) | [76.6%](/filings/0001493152-26-033207.md) | [80.9%](/filings/0001493152-26-033207.md) | | Operating margin | % | [(218.8%)](/filings/0001493152-23-022974.md) | [(159.9%)](/filings/0001493152-24-025344.md) | [(73.2%)](/filings/0001641172-25-020105.md) | [(17.8%)](/filings/0001493152-26-033207.md) | [10.6%](/filings/0001493152-26-033207.md) | | Net margin | % | [(380.8%)](/filings/0001493152-23-022974.md) | [(193.6%)](/filings/0001493152-24-025344.md) | [(116.8%)](/filings/0001641172-25-020105.md) | [(61.1%)](/filings/0001493152-26-033207.md) | [(15.0%)](/filings/0001493152-26-033207.md) | | Diluted EPS | $ per share | not reported | [(2.26)](/filings/0001493152-24-025344.md) | [(1.66)](/filings/0001641172-25-020105.md) | [(0.56)](/filings/0001493152-26-033207.md) | [(0.12)](/filings/0001493152-26-033207.md) | | Free cash flow | $m | [(15.2)](/filings/0001493152-23-022974.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/btcy/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Strengthening Families & Communities, LLC](/funds/1921196.md) | 2026-06-30 | $6.0k | 48,263 | | Unchanged | ## Recent filings [All 317 filings](/companies/btcy/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 23:04 ET | [8-K](/filings/0001493152-26-044407.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-044407 | | 2026-08-19 | 20:05 ET | [10-Q](/filings/0001493152-26-039209.md) | Quarterly report, period 2026-06-30 | 0001493152-26-039209 | | 2026-07-14 | 21:25 ET | [10-K](/filings/0001493152-26-033207.md) | Annual report, period 2026-03-31 | 0001493152-26-033207 | | 2026-05-01 | 21:28 ET | [8-K](/filings/0001493152-26-020939.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-020939 | | 2026-02-18 | 22:30 ET | [8-K](/filings/0001493152-26-007369.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-007369 | | 2026-02-11 | 21:29 ET | [10-Q](/filings/0001493152-26-006211.md) | Quarterly report, period 2025-12-31 | 0001493152-26-006211 | | 2025-12-19 | 22:29 ET | [S-1](/filings/0001493152-25-028614.md) | Registration statement | 0001493152-25-028614 | | 2025-11-18 | 21:05 ET | [8-K](/filings/0001493152-25-024061.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-25-024061 | | 2025-11-14 | 20:38 ET | [10-Q](/filings/0001493152-25-023361.md) | Quarterly report, period 2025-09-30 | 0001493152-25-023361 | | 2025-08-14 | 11:01 ET | [10-Q](/filings/0001641172-25-023709.md) | Quarterly report, period 2025-06-30 | 0001641172-25-023709 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001493152-26-033207.md), filed Jul 14, 2026. ## Forecast league Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c4900149-1155-48f0-b933-70f697effb91) ## About the filer - CIK: 1630113 - Tickers: BTCY - Exchange: OTC - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.